Castle | $1,000,000 | (Jun 27, 2025)
Handspring Health | $12,000,000 | (Jun 27, 2025)
DejaBlue | $8,000,000 | (Jun 27, 2025)
Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
Certify | $40,000,000 | (Jun 27, 2025)
Tacta Systems, Inc. | $7,000,000 | (Jun 27, 2025)
Antler Bio | $4,212,546 | (Jun 27, 2025)
Raphe mPhibr | $100,000,000 | (Jun 27, 2025)
DataBahn.ai | $17,000,000 | (Jun 27, 2025)
Klutch AI | $8,000,000 | (Jun 27, 2025)
Niural | $31,000,000 | (Jun 27, 2025)
Jarsy Inc | $5,000,000 | (Jun 27, 2025)
Spekter Games | $5,000,000 | (Jun 27, 2025)